WO1995006482A1 - COMPOSITION D'EMULSION A BASE DE 1α,24-(OH)2-VITAMINE D¿3? - Google Patents
COMPOSITION D'EMULSION A BASE DE 1α,24-(OH)2-VITAMINE D¿3? Download PDFInfo
- Publication number
- WO1995006482A1 WO1995006482A1 PCT/JP1994/001443 JP9401443W WO9506482A1 WO 1995006482 A1 WO1995006482 A1 WO 1995006482A1 JP 9401443 W JP9401443 W JP 9401443W WO 9506482 A1 WO9506482 A1 WO 9506482A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- oil
- cream
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Definitions
- the present invention relates to a novel 1 ⁇ , 24- (0 ⁇ ) 2 - about V. D 3 click stream agent. Further in detail the present invention is a principal agent 1, 24- (0H) 2 - is good skin permeability of V. D 3 good for 1 a, 24- (OH) 2 - about V. D 3 click stream agent. More specifically, the present invention relates to a pharmaceutical composition of the present invention, wherein the active ingredient 1a, 24— (0H) 2 -V.D 3 has good skin penetration and the active ingredient 1, 24- (0H) 2 -V.D 3 Improved stability, excellent physical stability as a cream, and excellent feel when applied to skin
- the Ca-regulating effect has already been clinically administered as an oral agent for so-called osteopenia such as osteoporosis and osteomalacia, and an excellent therapeutic effect has been recognized.
- the cell differentiation induction effect was also considered clinical application, albeit behind the Ca regulation effect.
- psoriasis is refractory skin captivated diseases were examined application of active V. D 3 compounds from the undifferentiated and proliferative ⁇ advance of epidermal cells is thought to cause.
- Psoriasis is administered orally because it is a disease of the outer skin layer of the skin. Local administration to the site of skin disease was more advantageous in terms of bioavailability than systemic administration such as injection administration, and it was possible to prevent systemic side effects.
- Dosage forms for topical administration to the skin include semi-solid preparations such as ointments and creams, tapes, cataplasms, and powders.Semi-solid preparations are considered in consideration of the pathology of psoriasis. It is suitable. 1, 24- (0H) 2 - (- see 68009 Pat Kokoku 3) already present inventors formulation of anhydrous-based ointments are disclosed by the by the ointment of V. D 3. Although a good therapeutic effect has been reported with this anhydrous ointment, since the ointment base is white petrolatum, it cannot be avoided to be greasy and sticky after application. For external application, an external preparation having a further improved feel was desired.
- the cream contains a large amount of water, is not sticky like an ointment, and has been used as an external preparation for a long time.
- it can be either oil-in-water (OZW) or water-in-oil (WZO).
- OZW oil-in-water
- WZO water-in-oil
- emulsion creams There are two types of emulsion creams and aqueous gel creams. When these three types are compared in a state where they are rubbed on the skin when applied, the aqueous gel cream shows that the polymer as the gel base precipitates on the skin and the water-in-oil type (W / 0 ) Emulsion cream has the drawback that the appearance color such as white does not disappear easily.
- the oil-in-water (OZW) emulsion cream has the advantage that the appearance color such as white easily disappears and is easy to use.
- psoriasis especially in the face, psoriasis often causes the appearance of the color to be easily erased, and the oil-in-water type that gives a good feel when applied, such as the appearance of the applied part is not noticeable, especially the applied part does not glitter.
- Emulsion creams are desired.
- Oil-in-water emulsion creams usually contain an oil phase consisting of a solid or semi-solid oil at room temperature and a liquid oil at room temperature. It is composed of an aqueous phase containing a humectant such as propylene glycol or glycerin, and a surfactant. (For general techniques related to these creams, see, for example, “New Cosmetic Science”, edited by Takeo Mitsui, 1993, published by Nanzando.)
- solid oil examples include hydrocarbons such as white petrolatum and solid paraffin; higher alcohols such as cetyl alcohol and stearyl alcohol; higher fatty acids such as palmitic acid; waxes such as beeswax and carnaubaro. Esters); sterol esters such as lanolin; and the above liquid oils include hydrocarbons such as liquid paraffin and squalane; medium-chain fatty acid triglycerides, armand oil, olive oil, Esters such as diisopropyl adipate are usually used
- nonionic surfactants and ionic surfactants are used alone or in combination of two or more as the above-mentioned surfactants, and surfactants are used for emulsification of oil-in-water emulsions. It is generally said that the HLB value of the agent is suitably in the range of about 8 to about 18. (For example, see “Dispersion. Chemistry of emulsification system” by Kitahara et al., 1988, Engineering Book, p. 63)
- JP-A-4 - The 210,903 Pat 1 ⁇ , 25- (0 ⁇ ) 2 - are emulsions of topical pharmaceutical compositions of V. D 3 is disclosed, cetyl alcohol, solid oil component such as steering Li alcohol ( A cream formulation containing a viscosity modifier and a liquid oil such as liquid paraffin (described as a lipophilic solubilizer) in the same specification.
- solid oil component such as steering Li alcohol
- a liquid oil such as liquid paraffin (described as a lipophilic solubilizer) in the same specification.
- 1 ⁇ , 25- (0 ⁇ ) 2 one V. 1 emulsion composition in D 3, 25- (0H) 2 - V.
- D chemical stability of about 6.5 to about a PH of It is stated that this can be achieved by adjusting to 7.5.
- W092Z 01454 Pat the same 91 Bruno 1280 Pat, calcium port preparative polyol or 20 (R) -22- Okisa one V.
- D 3 derivatives of the click Li one beam agent is disclosed, white Waseri down And a cream formulation containing a solid oil composed of, for example, cetostearyl alcohol and a liquid oil composed of liquid paraffin.
- creams or emulsion compositions are composed of components usually used in cream preparations (for example, as described above).
- JP-A-210903 describes that the pH is adjusted from about 6.5 to about 7.5 to stabilize the active ingredient, but other than that, Not even mentioned. In other words, there was no specific identification of the components constituting the oil phase or the components of the surfactant.
- the formulations disclosed in EP-A-0, 129, 003 or JP-A-60-174705 are sticky at the time of application, the application site is glaring, and under heating, or There was a problem in physical stability that the oil phase and the water phase easily separated under gravity load. Further, the formulation disclosed in Japanese Patent Application Laid-Open No. 4-210903 has a problem in physical stability that an oil phase and an aqueous phase are easily separated under heating or under gravitational load. With the prescription exemplified in the specification and the specification of JP-A-91 / 1280, glare at the application site could not be wiped out.
- an object of the present invention is to provide, 1 alpha of agent, 24- (0 ⁇ ) 2 one V. improves Kawatoriko permeability of D 3, as a result sufficient pharmacological effect is issued volatilizing, and its An object of the present invention is to provide a 1, 24— (0H) 2 -V.D 3 cream having improved chemical stability. The 1 alpha further improved feel during physical stability Contact and simultaneously applied, 24- (0 ⁇ ) 2 - it is to provide a V. D 3 click stream agent.
- the inventors of the present invention have conducted intensive studies to solve the above-mentioned problems, and as a result, the skin permeation of 24- (0H) 2 —V.D 3 , which is one of the main drugs, is a component of a cream agent. It is dependent on the type and amount of oil phase ingredients, 1 ⁇ , 24- (0 ⁇ ) chemical stability in 2 one V. D 3 of click streams agents depends greatly on the type and amount of surfactant.
- the physical stability of the creaming agent depends on the ratio of solid oil to liquid oil in the oil phase, and the feel during application depends on the type of liquid oil in particular.
- the present inventors have found that they are deeply involved and arrived at the present invention. The following describes the background to the above findings and the technical idea of the invention.
- the active substance in the cream at a concentration as close as possible to the saturation solubility in order to improve the skin penetration of the active substance in the cream.
- Shii is, 1, 24- (0H) 2 when one V.
- D 3 follows a prescribed normal click stream agent for hardly soluble in chemically unstable and also non-polar solvent, saturated such 1 ⁇ , 24- (OH) 2 in close concentration - it is very difficult to made present stably V. D 3.
- the surfactants constituting 2.5 to 7.5 parts by weight of the whole cream agent of the present invention are surfactants having an HLB value of about 5 or less, and HLB value is from about 8 to about 18, more preferred is 1 alpha properly is about 8 to about 12, 24- (0 ⁇ ) 2 - a high fraction distribution to the oil phase of V. D 3, thus a 1, 24- (0H) 2 - required der Rukoto the chemical stabilization of V. D 3 has been found.
- the present inventors consider the solid phase constituting the oil phase. It was found that the composition ratio between oil and liquid oil was important. In other words, the cleansing agent is subject to such severe conditions. In order to maintain a clean state even when the oil is placed under the following conditions, the ratio of solid oil to liquid oil in the oil phase (solid oil / liquid oil: weight ratio) is about
- the solid oil content in the cream formulation disclosed in EP-A-0,129,003 is 20 parts by weight of Millo®, and the liquid oil content is 40 parts by weight of liquid paraffin.
- the amount of solid oil to liquid oil was 0.5 or less, which was 1 part by weight of armored oil, that is, 41 parts by weight in total.
- the solid oil content in the cream formulation disclosed in JP-A-60-174705 is 10 parts by weight of white cellulose, 4 parts by weight of solid paraffin, 3 parts by weight of milow, 2 parts by weight of stearate.
- the liquid oil content was 25 parts by weight liquid paraffin and the olive oil 5 parts by weight, totaling 30 parts by weight.
- the weight ratio of solid oil to liquid oil was about 0.63.
- the solid oil content in the formulation of the composition for topical emulsion disclosed in Japanese Patent Application Laid-Open No. 21010/1991 was 1.5 parts by weight of cetyl alcohol, 2.5 parts by weight of stearyl alcohol, and 4 parts by weight in total.
- the liquid oil was 4 parts by weight of the liquid paraffin, and the weight ratio of the solid oil to the liquid oil was 1.
- the solid oil content in the cream formulation disclosed in the specification of W092 / 01454 or W091 / 1280 is 23 parts by weight in total of 17 parts by weight of white cellulose and 6 parts by weight of cetostearyl alcohol.
- the c fourth was 4.6 weight ratio of the solid oil component pairs liquid oil, the factors of the touch at the time click stream agent coating, generally click rie beam agent
- the ratio of oil phase should be as small as possible.
- the oil phase component is performed to select a good liquid oil tactile, 1 ⁇ , 24- (OH) 2 of the present invention - in the case of V. D 3 click stream agent, the above physical Since it is necessary to reduce the liquid oil content to 13 or less of the oil phase component from the viewpoint of mechanical stability, it is difficult to adopt such a general method.
- liquid oils generally belong to hydrocarbons and esters as described above.
- the present inventors have found that when squalane is used as the liquid oil component, the stickiness at the time of application is lower than when, for example, liquid paraffin used in the prior art is used. It has been found that an excellent feel at the time of application can be obtained, which is less, and the shininess at the application site is much less.
- An oil phase component consisting of
- the weight ratio between the solid oil and the liquid oil (the solid oil Z and the liquid oil) is about 2 or more.
- the higher alcohol comprises stearyl alcohol and acetyl alcohol
- the weight ratio of the stearyl alcohol to the higher alcohol (the stearyl alcohol Z the higher alcohol) is about 0.65 to about 0. 9.
- 50% by weight or more of the surfactant is one or more surfactants having an HLB value of about 5 or less, and the HLB of the entire surfactant is Value of about 8 to about 18 1, 24 - (0H) 2 - comprising V. D 3 click stream agent and all torque ream agents antipsoriatic agent.
- Figure 1 shows the experimental setup used in Reference Experiment 4. BEST MODE FOR CARRYING OUT THE INVENTION
- the oil phase component constituting the 1,24- (0H) 2 —V.D 3 cream agent of the present invention comprises 5 to 20 parts by weight of white cellulose and 5 to 15 parts by weight of higher alcohols It consists of solid oil and liquid oil consisting of 3 to 10 parts by weight of squalane.
- the white petrolatum of the present invention is obtained by decolorizing a mixture of hydrocarbons obtained from petroleum and refining the same.
- the standards specified by the Japanese Pharmacopoeia are used. Of these, 1, 24 - (0H) 2 - laid desired high purity for the stability of V. D 3, such as those peroxide value as 0.5 or less desirable arbitrariness.
- the higher alcohols of the present invention are a mixture of cetyl alcohol and stearyl alcohol, and the weight ratio of stearyl alcohol to the whole in the mixture is from about 0.65 to about 0.9. Among them, the range is preferably about 0.7 to about 0.9, particularly preferably about 0.70 to about 0.85.
- cetyl alcohol and stearyl alcohol are not pure. For example, there is also a mixture of about 0.7 of cetyl alcohol and about 0.3 of stearyl alcohol even though it is called cetyl alcohol, and further, about 0.6 to 0.4% of cetyl alcohol, such as what is called cetostearyl alcohol. There is also a mixture of about 0.3 and about 0.4 to about 0.7 of stearyl alcohol.
- the cetyl alcohol and stearyl alcohol of the present invention each refer to pure ones, and their mixing ratio is calculated based on them.
- the scurane of the present invention is a saturated hydrocarbon obtained by, for example, reducing the hydrocarbon obtained from shark liver oil living in the deep sea, and its standard is, for example, that specified in the chemical raw material standard. Used o
- solid oil and liquid oil may be added in addition to the above-mentioned white cellulose, higher alcohols and squalane.
- the solid oil include solid paraffin.
- the amount of the solid oil to be added may be within the range of maintaining the physical stability, which is one of the objects of the present invention. It is preferable that Z is not more than 10 parts by weight because a suitable hardness can be maintained as a creaming agent.
- the liquid oil include esters such as medium-chain fatty acid triglyceride, diisopropyl adipate, and isopropyl myristate.
- One objective is for example 1 a of the amount of addition of these liquid-like oil present invention, 24 - (0H) by as long as it is within the range of skin penetration of 2 one V. D 3 is maintained rather, the risk Waran It is preferable that the content of 3 Z be 10 parts by weight or less, because good skin permeability of 1, 24-(0H) 2 — V. D 3 can be maintained.
- the surfactant of the present invention is composed of two or more surfactants, the total of which is 2.5 to 7.5 parts by weight of the whole cream. In addition, more than 50% by weight of this surfactant may contain one or more surfactants having an HLB value of about 5 or less.
- the overall surfactant has an HLB value of about 8 to about 18. More preferably, it is about 8 to about 12.
- one or more surfactants having an HLB value of about 5 or less that constitute 50% by weight or more include, for example, sorbitan monoolate, sorbitan monostearate, and sorbitan monostearate.
- One or more surfactants selected from the group consisting of tansesquiolate, sorbitan trioleate, glyceryl monostearate, glyceryl monooleate, propylene glycol monostearate and the like can be used.
- the remaining surfactant is not particularly limited as long as it has an overall HLB value of about 8 to about 18, and more preferably about 8 to about 12, and is, for example, polyoxyethylene (30 or 40 or 60) sorbitan triolate, polyoxyethylene (60) hydrogenated castor oil.
- Sorbitan monolaurate, sorbitan monopalmitate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate Selected from the group consisting of polyoxyethylene (20) sorbitan monostearate, polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (10) monolaurate, and polyoxyethylene (23 or 25 or 30) cetyl ether.
- One or more surfactants are examples of surfactants.
- An antioxidant can be added to the oil phase component of the cream according to the present invention.
- an antioxidant butylhydroxytoluene, butylhydroxyanisole, d ⁇ -natocoprole, and the like, more preferably d-natocoprole, are added, and the amount added is usually from 0.001 to 5 0.0 parts by weight, more preferably 0.01 to 3.0 parts by weight.
- D 3 click streams may be added humectants, antiseptics, chelate agents, buffering agents and the like.
- humectants include propylene glycol, glycerin, and sorbitol
- the addition amount is 1 to 20 parts by weight, more preferably 2 to 15 parts by weight.
- preservatives include parabens such as methylparaben, propylparaben, and mixtures thereof; chlorobutanol; monothioglycerol; sorbic acid, potassium sorbate; and benzyl alcohol. It is 0.001 to 10.0 parts by weight, more preferably 0.01 to 5.0 parts by weight.
- Examples of the chelating agent include citric acid, sodium citrate; sodium edetate, and the like.
- the amount of the chelating agent is 0.001 to 5.0 parts by weight, more preferably 0.01 to 3.0 parts by weight. It is.
- Examples of the buffer include sodium dihydrogen phosphate, sodium dihydrogen phosphate, and the like, and the ratio required to adjust the pH of the aqueous phase component to 6.5 to 8.0. It is added at.
- the main drug of the present invention 1 ⁇ , 24— (0 ⁇ ) 2 — V.
- D 3 is 1, 24 (R)-(0H) 2 -D and 1, 24 (S)-(0H) 2 - of V. D 3, 1 a, 24 (R) - (OH) arbitrarily favored in that two one D 3 has excellent pharmacological activity thereof.
- a crystal is preferable from the viewpoint of purity among 24 (R) 1 (0H) 2 — V. D 3 , and for example, its monohydrate can be used.
- 1 of the present invention 24- (0H) 2 one V. D 3 1 a of the agent contained in the click stream agent, 24- (0H) 2 -V.
- Therapeutic skin diseases amount of D 3 is to be applied It is an effective amount and usually ranges from about 0.00005 to about 0.01% by weight as a concentration in the cream.
- the 1 ⁇ , 24- (OH) —V.D 3 cream agent of the present invention is the main drug as usual.
- D 3 The required amount of D3 is heated and dissolved in the oil phase component together with the surfactant, mixed with the aqueous phase component heated in the emulsifier, and then emulsified to homogenize It is manufactured by cooling.
- VD 3 click stream agent e.g. vulgaris psoriasis, pustular psoriasis, guttate psoriasis, Benigawa psoriasis, arthritis psoriasis, various psoriasis such as severe psoriasis Can be used for the treatment of Different forces by degrees, etc., for example 1 ⁇ , 24- (0 ⁇ ) 2 - is preferred arbitrariness of the concentration of V.
- D 3 is administered click stream agent 100 zg ⁇ 0.1 z gZ g 1 ⁇ several times a day.
- agents 1 alpha of the present invention, 24- (0 ⁇ ) 2 - Kawatoriko permeability of V. D 3 is good, and improved its chemical stability, physical as a further click stream agent excellent stability, 1 excellent feel during Kawatoriko coating, 24- (0H) 2 one V. D 3 click stream agent.
- the present invention provides a 24- (0H) 2 —V.D 3 cream having the same pharmacological activity as an anhydrous ointment of the same content in a clinical setting.
- it also has a good feel when applied to the skin, has excellent physical stability as an emulsion, and has an active ingredient 1, 24- (0H) 2 — V .
- D good 1 chemical stability of 3 ⁇ , 24- (OH) 2 - significance of V. D 3 click stream agent is provide the clinical field is extremely large.
- the healthy volunteers applied the sample cream to the forearms of five healthy subjects, (1) the stickiness at the time of application, (2) the ease with which white color disappeared, and (3) the adhesiveness after application.
- the feeling of stickiness and glare were evaluated on a five-point scale.
- the amount of the cream applied was 50 mg, which was applied to a 3 cm x 3 cm square part of the forearm.
- the five-point scale made the good ones bigger. 2. Test method for physical stability of cream
- Fig. 1 The experimental setup shown in Fig. 1 was used for this experiment.
- 1 is the captive skin
- 2 is the cream for the sample
- 3 is the sampling port
- 4 is one reservoir
- 5 is the cell.
- Cells maintained at 37 ° C, a sample of click streams agent is applied such that the 5 mg / cm 2 to Kawaomonbaka upper surface 1 of the reservoir fluid by sampling the reservoir fluid from the sampling for opening after a predetermined time , 24- (0H) 2 — V.
- D 3 was quantified by HPLC. (See below for quantitative method)
- lONmol of TPA is administered to 3 ⁇ 3 cm 2 of the back of a hair mouse in order to enhance the proliferation of epidermal cells.
- 50 mg of the test sample (cream) is administered to the administration group at the same site (not to the control group).
- the skin at the administration site is excised, and its 0DC activity is measured by the method of Chiba, K., et al. (Cancer Res., 44: 1387-1391 (1984)).
- suppressing ratios take it in the ratio of treated group relative to control group 0DC active, 1 a, 24- (0 ⁇ ) 2 - was used as an index of pharmacological activity of V. D 3 click stream agent.
- Classification number Component name Amount Main drug 1 1 a, 24 (R)-(0H) 2 —V.D 3 0.0002 parts by weight Solid oil 2 White ⁇ -Serine 10 parts by weight
- Sorbitan monostearate 1 part by weight
- Moisturizer 10 Polyethylene glycol 1500 2 parts by weight
- Moisturizer 8 pro helen li konore
- Te agent 5 set macrogol 3 parts by weight D propylene glycol cornole triple part preservative 7 chloride 1 chlorinated linoleic 1 saminium, 0. Oomp
- Example 1 Control Example 1, Cream Agent of Example 2, and White Cream of Example 1
- the beeswax was used instead of phosphorus (Comparative Example 6)
- the white color of Example 1 was replaced with stearyl acid (Comparative Example 7), and the white vase of Example 1 was used.
- a case in which lanolin was used instead of phosphorus (Control Example 8).
- a case in which stearyl acid was used in place of the higher alcohols in Example 1 (Control Example 9) was used.
- the sample was prepared by using 10 parts by weight of the creaming agent of Example 1, control examples 1, 2, 3, and 4, and 5 parts by weight of squalane of Example 1.
- Example 2 10 parts by weight of white cellulose, 8 parts by weight of stearyl alcohol, 2 parts by weight of cetyl alcohol, and 5 parts by weight of squalane of Example 1 were 7 parts by weight, 4 parts by weight, 1 part by weight, and 4 parts by weight, respectively.
- Example 3 13 parts by weight of 5 parts by weight of squalane of Example 1 (Comparative Example 12), 10 parts by weight of white cellulose, 8 parts by weight of stearyl alcohol, and 2 parts of cetyl alcohol of Example 1 6 parts, 4 parts, 1 part, and 10 parts by weight of 5 parts by weight and 5 parts by weight of screen, respectively
- Example 2 (; 2) jjn 4 Example 3 (; 3) No 4 Control Example 1 (Beeswax liquid paraffin 0.49 Yes 0.5
- Control 13 (; 1.1) Yes 1
- Control 14 (-white ⁇ -Serine squalane; 42.5
- Example 1 In addition to the creams of Example 1 and Controls 1 to 4, the samples were Comparative Examples 10 and 11 (see Reference Experiment 2), and the weight ratio of stearyl alcohol to cetyl alcohol of Example 1 was used. Were changed as shown in Table 5, and the creams of Examples 4 and 5 and Controls 14 to 21 were used. Also, click rie beam agent In this experiment, 1 in ointment, the concentration of 24- (0H) 2 -V. D 3 and 50 z gZ g.
- Example showing the limits of the oil phase or surfactant content of the creaming agent The creaming agents of the following Examples 9 and 10 were produced by changing the amount of the oil phase and the surfactant in Example 1. The nature of these click ream agents were shown to be click stream agent excellent in the same manner as also in Example 1 (each shown in Table 10 £ Example 9
- Example 1 - V. D 3 0.00005 parts by weight in place of 0.0002 parts by weight and the click stream agent (Example 11) and 0.01 parts by weight was click stream agent (Example 12 ) was manufactured. According to Experimental Method 3, the relative permeation amount was almost 99% when their skin penetration was compared with an anhydrous ointment (the same formulation as in Control Example 5) at the same concentration according to Experimental Method 3. Reference Experiment 9
- Creams were prepared by adding 11.52 parts by weight of diisopropyl adipate as the same component to 5 parts by weight of liquid oil squalane of Example 1 (Examples 13, 14 and Control 27, respectively). .
- the properties of the creams of Examples 13 and 14 are almost the same as those of the creams of Example 1.
- the relative permeability was inferior to 80%.
- Esters can be added in addition to squalane as a liquid oil component.
- solubility of 24— (0H) 2 —V.D 3 is too high, the skin permeability will decrease. It is estimated that it is limited to about 30%.
- the cream according to the present invention is excellent in not only containing 1, 24- (0H) 2 -1 V.D 3 but also excellent in skin penetration and excellent in chemical stability of the active ingredient, and is applied to the skin. feel when is good, and so also the physical stability of the emulsion is good, 1 ⁇ , 24- (0 ⁇ ) effective in the 2 one V. D 3 as a click stream agent skin and Can be applied to
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
- Detergent Compositions (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002148109A CA2148109C (en) | 1993-09-01 | 1994-09-01 | 1.alpha., 24-(oh)2-v.d.3 emulsion composition |
JP7508038A JP3045179B2 (ja) | 1993-09-01 | 1994-09-01 | 1α,24−(OH)▲下2▼−V.D▲下3▼乳剤性組成物 |
KR1019950701720A KR100221045B1 (ko) | 1993-09-01 | 1994-09-01 | 1알파,24-(oh)2-v.d3 유제성조성물 |
AT94925612T ATE195431T1 (de) | 1993-09-01 | 1994-09-01 | Emulsion auf der basis von 1-alpha,24-dihydroxy- vitamin d3 |
DK94925612T DK0667166T3 (da) | 1993-09-01 | 1994-09-01 | Emulsionspræparat med 1alpha, 24-(OH)2-vitamin D3 |
DE69425552T DE69425552T2 (de) | 1993-09-01 | 1994-09-01 | Emulsion auf der basis von 1-alpha,24-dihydroxy-vitamin d3 |
PL94308748A PL175492B1 (pl) | 1993-09-01 | 1994-09-01 | Farmaceutyczny preparat w postaci kremu |
SK592-95A SK279913B6 (sk) | 1993-09-01 | 1994-09-01 | Farmaceutický prostriedok vo forme krému |
EP94925612A EP0667166B1 (en) | 1993-09-01 | 1994-09-01 | 1-alpha,24-(oh)2-vitamin d3 emulsion composition |
US08/428,106 US5612327A (en) | 1993-09-01 | 1994-09-01 | 1α,24-(OH)2 -cholecalciferol emulsion composition and method for treating psoriasis |
NO19951639A NO312227B1 (no) | 1993-09-01 | 1995-04-28 | 1<alfa>,24-(OH)2-vitamin D3-emulsjonspreparat |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP21726193 | 1993-09-01 | ||
JP5/217261 | 1993-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995006482A1 true WO1995006482A1 (fr) | 1995-03-09 |
Family
ID=16701374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001443 WO1995006482A1 (fr) | 1993-09-01 | 1994-09-01 | COMPOSITION D'EMULSION A BASE DE 1α,24-(OH)2-VITAMINE D¿3? |
Country Status (17)
Country | Link |
---|---|
US (1) | US5612327A (ja) |
EP (1) | EP0667166B1 (ja) |
JP (1) | JP3045179B2 (ja) |
KR (1) | KR100221045B1 (ja) |
CN (1) | CN1082818C (ja) |
AT (1) | ATE195431T1 (ja) |
CA (1) | CA2148109C (ja) |
CZ (1) | CZ284261B6 (ja) |
DE (1) | DE69425552T2 (ja) |
DK (1) | DK0667166T3 (ja) |
ES (1) | ES2148340T3 (ja) |
NO (1) | NO312227B1 (ja) |
PL (1) | PL175492B1 (ja) |
PT (1) | PT667166E (ja) |
SG (1) | SG52313A1 (ja) |
SK (1) | SK279913B6 (ja) |
WO (1) | WO1995006482A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187763B1 (en) | 1998-03-04 | 2001-02-13 | Teijin Limited | Activated vitamin D3 emulsion-type lotions |
US6248779B1 (en) | 1995-04-21 | 2001-06-19 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
US6242434B1 (en) * | 1997-08-08 | 2001-06-05 | Bone Care International, Inc. | 24-hydroxyvitamin D, analogs and uses thereof |
DE19639816A1 (de) * | 1996-09-27 | 1998-04-02 | Hoechst Ag | Antimykotische Mittel mit hoher Wirkstofffreisetzung |
US20040039030A1 (en) * | 1996-09-27 | 2004-02-26 | Hoechst Akeengesellschaft | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US20020128240A1 (en) * | 1996-12-30 | 2002-09-12 | Bone Care International, Inc. | Treatment of hyperproliferative diseases using active vitamin D analogues |
US6566353B2 (en) * | 1996-12-30 | 2003-05-20 | Bone Care International, Inc. | Method of treating malignancy associated hypercalcemia using active vitamin D analogues |
US20030129194A1 (en) * | 1997-02-13 | 2003-07-10 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
AU762481C (en) * | 1998-03-27 | 2004-08-19 | Oregon Health Sciences University | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders |
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
EP2070911A2 (en) * | 2000-07-18 | 2009-06-17 | Bone Care International, Inc. | Stabilized 1Alpha-Hydroxy vitamin D |
CA2469119A1 (en) * | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060003950A1 (en) * | 2004-06-30 | 2006-01-05 | Bone Care International, Inc. | Method of treating prostatic diseases using a combination of vitamin D analogues and other agents |
US7094775B2 (en) * | 2004-06-30 | 2006-08-22 | Bone Care International, Llc | Method of treating breast cancer using a combination of vitamin D analogues and other agents |
NZ563560A (en) * | 2005-06-01 | 2009-11-27 | Stiefel Res Australia Pty Ltd | Vitamin formulation for treating a dermatological skin disorder |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6226223A (ja) * | 1985-07-25 | 1987-02-04 | Teijin Ltd | 乾癬治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1272953A (en) * | 1984-10-08 | 1990-08-21 | Yuji Makino | Pharmaceutical composition for external use containing active-type vitamin d.sub.3 |
JPH0774144B2 (ja) * | 1986-03-12 | 1995-08-09 | 久光製薬株式会社 | 尿素を含有する皮膚用組成物 |
GB9226860D0 (en) * | 1992-12-23 | 1993-02-17 | Leo Pharm Prod Ltd | Novel treatment |
-
1994
- 1994-09-01 KR KR1019950701720A patent/KR100221045B1/ko not_active IP Right Cessation
- 1994-09-01 AT AT94925612T patent/ATE195431T1/de active
- 1994-09-01 CN CN94190728A patent/CN1082818C/zh not_active Expired - Lifetime
- 1994-09-01 DK DK94925612T patent/DK0667166T3/da active
- 1994-09-01 PL PL94308748A patent/PL175492B1/pl unknown
- 1994-09-01 JP JP7508038A patent/JP3045179B2/ja not_active Expired - Lifetime
- 1994-09-01 PT PT94925612T patent/PT667166E/pt unknown
- 1994-09-01 US US08/428,106 patent/US5612327A/en not_active Expired - Lifetime
- 1994-09-01 CZ CZ951132A patent/CZ284261B6/cs not_active IP Right Cessation
- 1994-09-01 ES ES94925612T patent/ES2148340T3/es not_active Expired - Lifetime
- 1994-09-01 SK SK592-95A patent/SK279913B6/sk not_active IP Right Cessation
- 1994-09-01 WO PCT/JP1994/001443 patent/WO1995006482A1/ja active IP Right Grant
- 1994-09-01 EP EP94925612A patent/EP0667166B1/en not_active Expired - Lifetime
- 1994-09-01 CA CA002148109A patent/CA2148109C/en not_active Expired - Lifetime
- 1994-09-01 SG SG1996002669A patent/SG52313A1/en unknown
- 1994-09-01 DE DE69425552T patent/DE69425552T2/de not_active Expired - Lifetime
-
1995
- 1995-04-28 NO NO19951639A patent/NO312227B1/no not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6226223A (ja) * | 1985-07-25 | 1987-02-04 | Teijin Ltd | 乾癬治療剤 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248779B1 (en) | 1995-04-21 | 2001-06-19 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
US6306898B1 (en) | 1995-04-21 | 2001-10-23 | Sekisui Kaisha Kogyo Kabushiki Kaisha | External preparations for the treatment of dermatoses |
US6187763B1 (en) | 1998-03-04 | 2001-02-13 | Teijin Limited | Activated vitamin D3 emulsion-type lotions |
US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
Also Published As
Publication number | Publication date |
---|---|
PL308748A1 (en) | 1995-08-21 |
NO951639D0 (no) | 1995-04-28 |
EP0667166A1 (en) | 1995-08-16 |
PT667166E (pt) | 2001-02-28 |
DE69425552T2 (de) | 2001-04-19 |
SG52313A1 (en) | 1998-09-28 |
CZ113295A3 (en) | 1995-11-15 |
CN1082818C (zh) | 2002-04-17 |
PL175492B1 (pl) | 1999-01-29 |
EP0667166B1 (en) | 2000-08-16 |
US5612327A (en) | 1997-03-18 |
DE69425552D1 (de) | 2000-09-21 |
ES2148340T3 (es) | 2000-10-16 |
CN1114824A (zh) | 1996-01-10 |
CA2148109A1 (en) | 1995-03-09 |
CZ284261B6 (cs) | 1998-10-14 |
CA2148109C (en) | 1999-11-23 |
ATE195431T1 (de) | 2000-09-15 |
SK279913B6 (sk) | 1999-05-07 |
KR100221045B1 (ko) | 1999-09-15 |
JP3045179B2 (ja) | 2000-05-29 |
NO951639L (no) | 1995-06-30 |
SK59295A3 (en) | 1995-12-06 |
EP0667166A4 (en) | 1995-11-02 |
DK0667166T3 (da) | 2000-10-16 |
KR950703998A (ko) | 1995-11-17 |
NO312227B1 (no) | 2002-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995006482A1 (fr) | COMPOSITION D'EMULSION A BASE DE 1α,24-(OH)2-VITAMINE D¿3? | |
JP4046363B2 (ja) | 活性型ビタミンd3乳剤性ローション剤 | |
EP1758588B1 (fr) | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises. | |
JP5873439B2 (ja) | ビタミンd類似体および溶媒と界面活性剤の混合物を含む皮膚組成物 | |
JP2008502645A (ja) | 油性相中にコルチコイドとビタミンd誘導体との組み合わせを含むスプレー形態の組成物 | |
EP0103910A1 (en) | Emollient-containing skin conditioning compositions | |
JP2660198B2 (ja) | コルチコステロイド含有外用クリーム製剤 | |
JPH0459292B2 (ja) | ||
EP0103911A1 (en) | Emollient-containing topical pharmaceutical compositions | |
JPH0676328B2 (ja) | ステロイドクリ−ム製剤 | |
AU674411B2 (en) | Compositions for the treatment of inflammatory proliferative skin disease and their use | |
CA2074503C (en) | Pharmaceutical formulation containing penciclovir | |
JPS61204109A (ja) | 乳化型の外用組成物 | |
JP2865867B2 (ja) | ペンシクロビル含有の局所用組成物 | |
EP1852120A1 (en) | Ointment | |
JPH05331050A (ja) | 消炎鎮痛外用剤 | |
JPH05331049A (ja) | 消炎鎮痛外用剤 | |
HU231334B1 (hu) | Apremilaszt tartalmú topikális készítmény | |
WO2016166913A1 (ja) | 皮膚用の医薬組成物 | |
CA2156396A1 (en) | Stable dermatologic preparation containing mycophenolic acid | |
JPH05331048A (ja) | 消炎鎮痛外用剤 | |
HU218585B (hu) | 1-alfa,24-(OH)2-V.D3-at tartalmazó emulzió psoriasis kezelésére | |
WO2003092704A1 (fr) | Preparation externe de vidarabine a propriete systemique amelioree |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94190728.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN CZ HU JP KR NO PL SK US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2148109 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08428106 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994925612 Country of ref document: EP Ref document number: PV1995-1132 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 59295 Country of ref document: SK |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994925612 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1995-1132 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1995-1132 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994925612 Country of ref document: EP |